Brief: Elicera Therapeutics Q2 Operating Loss Widens To Sek 5.8 Mln
29/08/2024 07:34
Aug 29 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* Q2 LOSS FOR PERIOD AMOUNTED TO SEK -5,622,779 (-4,335,852)
* Q2 OPERATING PROFIT/LOSS AMOUNTED TO SEK -5,841,409 (-4
466 286)
Source text for Eikon: ID:nWkr4Pz75t
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application